Literature DB >> 16844698

Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.

A W A M van Rijthoven, J W J Bijlsma, M Canninga-van Dijk, R H W M Derksen, J A G van Roon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16844698     DOI： 10.1093/rheumatology/kel227

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  10 in total

1.  A practical approach to screening psoriasis patients for therapy with biologic agents.

Authors: 
Journal:  J Clin Aesthet Dermatol       Date:  2008-09

2.  A practical approach to monitoring patients on biological agents for the treatment of psoriasis.

Authors:  Jason J Emer; Amylynne Frankel; Joshua A Zeichner
Journal:  J Clin Aesthet Dermatol       Date:  2010-08

3.  A patient with ankylosing spondylitis who developed infliximab-induced lupus and treated with etanercept.

Authors:  Özgür Akgül; Gamze Kılıç; Erkan Kılıç; İsa Cüce; Salih Özgöçmen
Journal:  Rheumatol Int       Date:  2012-12-22       Impact factor: 2.631

4.  Adalimumab in the therapy of uveitis in childhood.

Authors:  Sabine Biester; Christoph Deuter; Hartmut Michels; Renate Haefner; Jasmin Kuemmerle-Deschner; Deshka Doycheva; Manfred Zierhut
Journal:  Br J Ophthalmol       Date:  2006-10-11       Impact factor: 4.638

5.  Adalimumab-induced lupus serositis.

Authors:  Dearbhla Kelly; Oisin O'Connell; Michael Henry
Journal:  BMJ Case Rep       Date:  2015-03-04

6.  Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis.

Authors:  Maurizio Benucci; Gianantonio Saviola; Paola Baiardi; Emanuela Cammelli; Mariangela Manfredi
Journal:  Clin Rheumatol       Date:  2007-10-10       Impact factor: 2.980

7.  Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment.

Authors:  Tiina Levälampi; Markku Korpela; Katriina Vuolteenaho; Eeva Moilanen
Journal:  Rheumatol Int       Date:  2007-09-06       Impact factor: 2.631

8.  Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature.

Authors:  Angela Y Moore; Blakely S Richardson
Journal:  Clin Cosmet Investig Dermatol       Date:  2010-04-19

Review 9.  Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians?

Authors:  Kevin Didier; Loïs Bolko; Delphine Giusti; Segolene Toquet; Ailsa Robbins; Frank Antonicelli; Amelie Servettaz
Journal:  Front Immunol       Date:  2018-03-26       Impact factor: 7.561

10.  Anti-Tumor Necrosis Factor-α Induced Systemic Lupus Erythematosus().

Authors:  Hani Almoallim; Yahya Al-Ghamdi; Haneen Almaghrabi; Omnia Alyasi
Journal:  Open Rheumatol J       Date:  2012-11-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.